Prelude Therapeutics Stock Today
| PRLD Stock | USD 1.19 0.04 3.48% |
Performance1 of 100
| Odds Of DistressOver 75
|
Prelude Therapeutics is trading at 1.19 as of the 30th of January 2025, a 3.48 percent increase since the beginning of the trading day. The stock's lowest day price was 1.1. Prelude Therapeutics has a very high chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. The performance scores are derived for the period starting the 1st of November 2024 and ending today, the 30th of January 2025. Click here to learn more.
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. The company was incorporated in 2016 and is headquartered in Wilmington, Delaware. The company has 42.18 M outstanding shares of which 3.12 M shares are at this time shorted by private and institutional investors with about 4.53 trading days to cover. More on Prelude Therapeutics
Moving together with Prelude Stock
| 0.66 | PFE | Pfizer Inc Earnings Call This Week | PairCorr |
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Prelude Stock Highlights
| President Officer | Edna MD |
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) |
| Financial Strength | |
Prelude Therapeutics (PRLD) is traded on NASDAQ Exchange in USA. It is located in 175 Innovation Boulevard, Wilmington, DE, United States, 19805 and employs 128 people. Prelude Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 63.02 M. Prelude Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 42.18 M outstanding shares of which 3.12 M shares are at this time shorted by private and institutional investors with about 4.53 trading days to cover.
Prelude Therapeutics currently holds about 246.3 M in cash with (107.06 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.19, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Prelude Therapeutics Probability Of Bankruptcy
Ownership AllocationPrelude Therapeutics owns a total of 42.18 Million outstanding shares. The majority of Prelude Therapeutics outstanding shares are owned by third-party entities. These institutional holders are usually referred to as non-private investors looking to secure positions in Prelude Therapeutics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Prelude Therapeutics. Please pay attention to any change in the institutional holdings of Prelude Therapeutics as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Prelude Ownership Details
Prelude Therapeutics Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. Prelude Therapeutics market risk premium is the additional return an investor will receive from holding Prelude Therapeutics long position in a well-diversified portfolio.
| Risk Adjusted Performance | 0.0324 | |||
| Jensen Alpha | 0.0899 | |||
| Total Risk Alpha | (0.68) | |||
| Sortino Ratio | 0.0251 |
Prelude Stock Against Markets
Prelude Therapeutics Corporate Management
| Laurent MBA | Chief Officer | Profile | |
| William MD | Senior Development | Profile | |
| Naveen Babbar | Senior Medicine | Profile | |
| Neelesh MD | VP Devel | Profile | |
| Aimee Crombie | Senior Operations | Profile | |
| Madhu Pudipeddi | Senior Operations | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Prelude Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. For information on how to trade Prelude Stock refer to our How to Trade Prelude Stock guide.You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Prelude Therapeutics. If investors know Prelude will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Prelude Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Prelude Therapeutics is measured differently than its book value, which is the value of Prelude that is recorded on the company's balance sheet. Investors also form their own opinion of Prelude Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Prelude Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Prelude Therapeutics' market value can be influenced by many factors that don't directly affect Prelude Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Prelude Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Prelude Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Prelude Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.